HEALTH
Study: Access to targeted lung cancer drug is cost-prohibitive globally
![Study: Access to targeted lung cancer drug is cost-prohibitive globally](https://connecticutnewspress.com/wp-content/uploads/2024/05/10219-study-access-to-targeted-lung-cancer-drug-is-cost-prohibitive-globally.jpg)
Many countries with national health care systems or payers such as insurance companies use cost-effectiveness analyses to decide whether to cover new medicines, balancing treatment costs with potential health benefits…